RIPK3 and inflammatory bowel disease: It is most likely that more work is required to clearly define whether RIPK3 directly communicates with the abovementioned signaling molecules, whether necroptosis-dependent or independent machinery is involved in CRC tumorigenesis, and whether increasing the expression of RIPK3 in the colon may be considered as a therapeutic strategy for human CRC and IBD-related CRC patients.